UNITED STATES SECURITIES AND EXCHANGE COMMISSION December 21, 2017

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

CRISPR Therapeutics AG

File No. 001-37923 - CF#35797

CRISPR Therapeutics AG submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on December 18, 2017.

Based on representations by CRISPR Therapeutics AG that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1 through December 17, 2027 Exhibit 10.2 through December 17, 2027

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary